EFG International AG Takes $13.26 Million Position in Natera, Inc. $NTRA

EFG International AG purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 48,845 shares of the medical research company's stock, valued at approximately $13,263,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Trust Co. of Vermont purchased a new stake in shares of Natera during the second quarter worth $26,000. Elevation Wealth Partners LLC purchased a new position in shares of Natera in the second quarter valued at $30,000. Reflection Asset Management purchased a new position in shares of Natera in the fourth quarter valued at $29,000. Rakuten Securities Inc. bought a new stake in shares of Natera during the 2nd quarter valued at $35,000. Finally, Palladiem LLC bought a new stake in shares of Natera during the 4th quarter valued at $31,000. 99.90% of the stock is owned by institutional investors.

Insider Transactions at Natera

In other news, CFO Michael Burkes Brophy sold 478 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16. Following the transaction, the chief financial officer directly owned 51,637 shares in the company, valued at approximately $14,159,898.14. This represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $267.99, for a total value of $79,057.05. Following the transaction, the insider directly owned 183,774 shares in the company, valued at approximately $49,249,594.26. This represents a 0.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 177,955 shares of company stock worth $40,704,193. Company insiders own 5.05% of the company's stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $336.71 on Wednesday. The company's fifty day moving average price is $278.79 and its 200-day moving average price is $231.01. The firm has a market capitalization of $48.53 billion, a price-to-earnings ratio of -247.58 and a beta of 1.51. Natera, Inc. has a one year low of $157.43 and a one year high of $337.12.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the firm posted ($0.74) EPS. The firm's revenue was up 37.7% compared to the same quarter last year. As a group, equities research analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Canaccord Genuity Group set a $375.00 target price on Natera in a research note on Friday, August 7th. Guggenheim upped their price target on Natera from $290.00 to $360.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. UBS Group set a $260.00 price objective on shares of Natera in a research report on Wednesday, June 24th. Wells Fargo & Company boosted their price objective on shares of Natera from $220.00 to $284.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. Finally, Barclays reaffirmed an "overweight" rating and set a $340.00 target price on shares of Natera in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source